- ROUNDTABLE: Pharmacy’s future in sync with technology
- EXPERT BLOG: Provider status for pharmacists — one way or another
- Dr. Smith's Diaper Rash Ointment
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
PITTSBURGH — The World Health Organization has approved three generic second-line treatments for HIV made by Mylan, the drug maker said Tuesday. The drugs will be delivered to people in developing countries living with HIV and AIDS.
Subsidiary Mylan Labs won approval for atazanavir capsules in the 300-mg strength and ritonavir tablets in the 100-mg strength with tenofovir disoproxil fumarate and lamivudine tablets in the 300-mg/300-mg strength; a fixed-dose combination of atazanavir sulfate and ritonavir tablets in the 300-mg/100-mg strength; and a fixed-dose combination tablet of abacavir sulfate, lamivudine and zidovudine in the 300-mg/150-mg/300-mg strength.
Atazanavir, ritonavir, tenofovir disoproxil fumarate and lamivudine are generic versions of Bristol-Myers Squibb's Reyataz, Abbott Labs' Norvir, Gilead Sciences Viread and GlaxoSmithKline's Epivir, respectively.